Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the sale, the insider now directly owns 195,840 shares in the company, valued at approximately $2,228,659.20. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11. The company has a fifty day moving average of $14.58 and a 200-day moving average of $25.27. Dyne Therapeutics, Inc. has a 52-week low of $11.18 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Piper Sandler decreased their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.85.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Dyne Therapeutics in the 3rd quarter worth $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the 3rd quarter worth about $36,000. US Bancorp DE increased its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Dyne Therapeutics in the 4th quarter worth about $50,000. Finally, KBC Group NV increased its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.